|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-2.02/-23.48
|
企業價值
5.50M
|
資產負債 |
每股賬面淨值
0.76
|
現金流量 |
現金流量率
--
|
損益表 |
收益
--
|
每股收益
--
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/06/01 04:55 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader. |